MediPharm Labs Corp (MEDIF)

[DS CPA]

Sure, but coronavirus doesn’t impact this as much as others. Or even if we say it impacts it the same, why is this at about 1/3 of its 2020 high of $3.41 (MEDIF ticker; $1.21 as of this posting) whereas the S&P is only about 25% off the highs (eyeballed using SPY chart)?

I realize that this is an imprecise comparison, but I just want to offer the standpoint that this has been beaten down too far to begin with. But I guess I can only be so surprised that the value is being missed here given that it’s been that way for a while now.

This moved on analyst downgrades when the price targets are still multiple dollars above current level. The action here is very hard to understand. I would love to be educated by anyone who feels they can reconcile the value here (raw numbers) to the current share price. Maybe there is something I’m missing.